Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Canbridge Pharmaceuticals Inc.
Headquarters: Beijing, China
Website: http://www.canbridgepharma.com...
Year Founded: 2012
Status: Public
Industry Sector: HealthTechnology
CEO: James Xue, PhD, MBA
Number Of Employees: 100
Enterprise Value: $54,416,924
PE Ratio: -0.14
Exchange/Ticker 1: HKEX:1228
Exchange/Ticker 2: N/A
Latest Market Cap: $7,706,049
BioCentury | Nov 20, 2024
Discovery & Translation
Science Spotlight: A new obesity target may avoid nausea, muscle loss
BioCentury’s roundup of translational innovation: Embark/Novo discover new obesity target, Canbridge delivers large DMD gene, and more
BioCentury | Jun 2, 2023
Product Development
June 2 Quick Takes: Kisqali cuts recurrence risk in broad breast cancer population
Plus: BioNTech, OncoC4 build case for CTLA-4 product with lung cancer readout, and updates from Takeda, Poseida, Canbridge and more
BioCentury | Oct 5, 2022
Deals
LogicBio takeout brings new skills, platform to Alexion
AZ unit finds entry point to gene therapy in $68M acquisition
BioCentury | Jul 5, 2022
Management Tracks
Health Secretary Javid among ministers quitting U.K. government
Plus Hering made permanent CEO at Adagio and updates from Canbridge, Catalent, Nanoscope, and more
BioCentury | May 13, 2022
Management Tracks
New CEOs at CorMedix, Medigene
Plus updates from Elicio, Rejuvenate, Canbridge and more
BioCentury | Dec 11, 2021
Product Development
Dec. 10 Quick Takes: UCB’s rozanolixizumab meets in Phase III
Plus: Vifor-Angion product misses and updates from Arvinas-Pfizer, Canbridge, Totus and more
BioCentury | Apr 28, 2021
Product Development
April 27 Quick Takes: Merck, Gilead move to expand access to COVID-19 antivirals; plus Exscientia-Softbank, Lilly, Aldeyra, LogicBio, Canbridge, Daiichi, Ultivue, Provention
Initiatives by Merck & Co. Inc. (NYSE:MRK) and Gilead Sciences Inc. (NASDAQ:GILD) will expand availability of the companies’ antivirals in India as the country’s COVID-19 crisis
BioCentury | Mar 16, 2021
Deals
March 15 Quick Takes: Canada’s CPP leads insitro’s $400M series C; plus Bicara, Aveo, Gilead-Merck and more
Insitro Inc. said existing investor Canada Pension Plan Investment Board led its new $400 million series C round, which builds on a $143 million series B closed in May 2020. Also backing the
BioCentury | Feb 2, 2021
Management Tracks
Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem
Gene editing play CRISPR Therapeutics AG (NASDAQ:CRSP) hired Philippe Drouet as chief commercial officer. He was SVP, global oncology marketing & market access at Merck & Co. Inc. (NYSE:MRK),
Items per page:
1 - 10 of 38